Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an ...

Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...

US biopharma Vertex Pharmaceuticals today announced results from its Phase II study of suzetrigine, an investigational, oral, ...

Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...

A new, presumably more precise or, hopefully, more relevant, pain scale, named the Detroit Interventional Pain Management ...

In a small clinical study, researchers in the US examined the nature of new-onset pain reported by people with long COVID and explored potential associations between long COVID symptoms and pain.

When it comes to clearing up your eyebrow dandruff, the right approach depends on what’s causing your shedding in the first ...

The scale lists the numbers one through ten with the number one representing the absence of pain and the number ten representing the worst pain imaginable. The nurse should explain the scale to ...